Abstract library

194 results for "ssa".
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience
Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: everolimus SSA
#1503 Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study
Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Roberto Buzzoni
#1593 Role of SSA in the Management of Multiple Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 g-NENs associated with autoimmune chronic atrophic gastritis have high risk of recurrence but rare metastasis. Most type 1 patients are managed by endoscopic approach. The clinical benefit of somatostatin analogues (SSA) for type 1 g-NENs is controversial.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Huang-Ying Tan
Authors: Li Y L, Dou D, Tan H Y, ...
Keywords: SSA, gastric nen, type 1
#972 Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)
Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Antongiulio Faggiano
Keywords: NET, SSA, G1, G2, WHO classification
#993 Analysis of Somatostatin Receptors Expression in Neuroendocrine Tumors
Introduction: Clinical studies have suggested anti-tumor efficacy of somatostatin analog (SSA) in the treatment of neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Tingting Li
Authors: Li T, Qian Z, Ter-Minassian M, Chan J A, ...
Keywords: SSTR2, SSA, NET, OS, PFS
#1195 Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.
Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Keywords: Biomarker, SSA
#1357 Type 1 Gastric Neuroendocrine Tumor with SAPHO Syndrome Effectively Treated by Octreotide:A Case Report
Introduction: Type 1 gastric neuroendocrine tumor (gNET) which is associated with chronic atrophic gastritis type A can be treated with SSA for the recurrence. SAPHO syndrome characterized by synovitis, acne, pustulosis, hyperostosis and osteitis is a kind of rare aseptic inflammation, which is thought to be related with abnormal autoimmune. Presently, there is no satisfied treatment for this illness.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Dou D, Wu Y T, Tan H, ...
Keywords: gnet, SAPHO syndrome, SSA
#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Teo L, Hearn K, Bernstone G, Wright R, ...
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis